Abstract: SA-PO750
SARS-CoV-2 Vaccination in Patients with Pauci-Immune Glomerulonephritis: A Multicenter Study
Session Information
- ANCA-Associated Vasculitis, Anti-GBM Disease, and Other RPGN
October 26, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Sardeli, Angeliki, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece
- Dounousi, Evangelia, Panepistemio Ioanninon, Ioannina, Epirus, Greece
- Gkalitsiou, Dimitra, Geniko Nosokomeio Athenon Giorgos Gennematas, Athens, Attike, Greece
- Kantartzi, Konstantia, Demokriteio Panepistemio Thrakes, Komotini, East Macedonia and Thrace, Greece
- Pelagia, Kriki, Demokriteio Panepistemio Thrakes, Komotini, East Macedonia and Thrace, Greece
- Liakopoulos, Vassilios, Aristoteleio Panepistemio Thessalonikes, Thessalonike, Greece
- Marinaki, Smaragdi, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Greece
- Panagiotis, Giannakopoulos, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece
- Moustakas, Georgios, Geniko Nosokomeio Athenon Giorgos Gennematas, Athens, Attike, Greece
- Lionaki, Sophia, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece
Background
SARS-CoV-2 vaccination has been shown crucial in stemming the pandemic. This study aimed to describe adverse events associated with SARS-CoV-2 vaccination in patients with a history of pauci-immune glomerulonephritis (PIGN).
Methods
A retrospective analysis was conducted in individuals with PIGN who received the SARS-CoV-2 vaccine, excluding those in ESKD prior to vaccination. Recorded data included histopathological diagnosis, immunosuppressive regimens, clinical outcomes, vaccination type, and related adverse events.
Results
A cohort of 69 individuals diagnosed with PIGN, with an age of 59.6 (±17.5) years, was studied, of whom 36(53.7%) were females. Of these, 34(50.7%) had a medical history of hypertension, and 16(23.9%) type 2 diabetes. Induction therapy was administered in 66(98.5%) cases, with 87.7% of them achieving remission. 50(74.6%) patients received maintenance therapy and 50 (94.3%) were vaccinated against SARS-CoV-2, within 79.5(±70.8) months from the diagnostic biopsy with 3.2(±1.0) doses. At vaccination, 90% of patients were in remission and 44% were on immunosuppression. 26% of patients reported systemic adverse events and 62% local reactions after vaccination. 2(4.3%) patients experienced a relapse of PIGN, within 5.7 (±3.4) months from the first dose.
Conclusion
SARS-CoV-2 vaccination was well-tolerated, with non-significant impact on PIGN relapse probability. Local side effects were common, seen in the majority of patients, while systemic ones occurred in 20.4% of them.
Demographics, baseline characteristics and adverse events of patienst with PIGN following vaccination SARS-CoV-2 vaccination.
| Parameter Ν (%) or mean (SD) | Ν=69 |
| Age at PIGN diagnosis (years) | 61,75(15,55) |
| Sex (male) | 32 (46,3) |
| Time since kidney biopsy (months) | 76,1 (60,9) |
| Induction treatment Glucocorticoids Cyclophosphamide Mycophenolate mofetil Rituximab | 65 (97,0) 55 (83,3) 2 (3,0) 11 (18,0) |
| Maintenance treatment Rituximab AZA | 20 (39,2) 23 (45,0) |
| First outcome of PIGN Remission Resistant disease | N=63 58 (92,0) 5 (7,9) |
| Number of doses | 3,2 (1) |
| Adverse Events Systematic Arthralgias Myalgias Headache Fever Diarrhea Local Pain | 10 (20,4) 2 (4,25) 5 (10,6) 7 (14,9) 5 (10,9) 2 (4,25) 27 (55,1) 12 (24,5) |